Zhang Weidong, Cui Dong, Shi Kefeng, Chen Maolin, Zhang Binbin, Qian Rulin
Department of Thoracic Surgery, Henan Provincial Chest Hospital, Zhengzhou University, Zhengzhou, Henan, China.
Henan Provincial Mediastinoscope Diagnosis and Treatment Center, Zhengzhou, Henan, China.
Front Oncol. 2023 Apr 19;13:1110962. doi: 10.3389/fonc.2023.1110962. eCollection 2023.
At present, minimally invasive radical esophagectomy is the main surgical method for esophageal cancer treatment, but it has inherent limitations. We have developed a novel method of radical esophagectomy without thoracotomy to improve this situation, namely, by using EMLE. We evaluated the feasibility and safety of expandable mediastinoscopic and laparoscopic radical esophagectomy (EMLE) through a retrospective analysis.
From January 2019 to June 2022, we successfully performed 106 cases of radical resection of esophageal cancer with this new surgical technique, gradually improved the surgical path, and recorded the perioperative data and postoperative complications of all patients.
The operation was successfully performed in all patients except for two patients who required a switch to open surgery. The mean operation time was 171.11 ± 33.29 min and the mean intraoperative blood loss was 93.53 ± 56.32 ml. The mean number of removed lymph nodes was 23.59 ± 5.42. The postoperative complications included pneumonia (3.77%), recurrent laryngeal nerve palsy (1.89%), anastomotic leak (14.15%), pleural effusion (5.66%), chylothorax (2.83%), and reoperation (4.72%). All complications were graded I-III per the Clavien-Dindo classification. No perioperative death was recorded.
Expandable mediastinoscopic and laparoscopic radical esophagectomy is feasible for radical resection of esophageal cancer, with good therapeutic effect and safety. Because of its minimal impact on patients and convenient operation, it is a novel surgical option for patients with esophageal cancer and is expected to become a standard surgical method for radical esophagectomy in the future.
目前,微创根治性食管切除术是食管癌治疗的主要手术方式,但存在固有局限性。我们开发了一种不开胸的新型根治性食管切除术方法,即使用可扩展纵隔镜和腹腔镜根治性食管切除术(EMLE)来改善这种情况。我们通过回顾性分析评估了可扩展纵隔镜和腹腔镜根治性食管切除术(EMLE)的可行性和安全性。
2019年1月至2022年6月,我们使用这种新手术技术成功进行了106例食管癌根治性切除术,逐步改进手术路径,并记录了所有患者的围手术期数据和术后并发症。
除2例患者转为开放手术外,所有患者手术均成功。平均手术时间为171.11±33.29分钟,平均术中出血量为93.53±56.32毫升。平均清扫淋巴结数为23.59±5.42枚。术后并发症包括肺炎(3.77%)、喉返神经麻痹(1.89%)、吻合口漏(14.15%)、胸腔积液(5.66%)、乳糜胸(2.83%)和再次手术(4.72%)。所有并发症根据Clavien-Dindo分类为I-III级。无围手术期死亡记录。
可扩展纵隔镜和腹腔镜根治性食管切除术用于食管癌根治性切除是可行的,具有良好的治疗效果和安全性。因其对患者影响极小且操作方便,是食管癌患者的一种新型手术选择,有望成为未来根治性食管切除术的标准手术方法。